VISKAZIDE DIN 00568635
Health Canada record
| Active ingredient(s) | PINDOLOL 10 MG; HYDROCHLOROTHIAZIDE 50 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C07CA03 PINDOLOL AND OTHER DIURETICS |
| Original market date | 31-Dec-1983 |
| Current status date | 30-Sep-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Xediton Pharmaceuticals Inc — licence 101770, currently licensed, last inspection rating C (2026-06-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PINDOLOL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00869007 | TEVA-PINDOLOL | TEVA CANADA LIMITED | Tablet | PINDOLOL 5 MG | Marketed |
| 00869023 | TEVA-PINDOLOL | TEVA CANADA LIMITED | Tablet | PINDOLOL 15 MG | Marketed |
| 00869015 | TEVA-PINDOLOL | TEVA CANADA LIMITED | Tablet | PINDOLOL 10 MG | Marketed |
| 00755885 | APO-PINDOL TAB 10MG | APOTEX INC | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 00755893 | APO-PINDOL TAB 15MG | APOTEX INC | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 00755877 | APO-PINDOL TAB 5MG | APOTEX INC | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 02231650 | DOM-PINDOLOL | DOMINION PHARMACAL | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 02238047 | DOM-PINDOLOL | DOMINION PHARMACAL | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 02238046 | DOM-PINDOLOL | DOMINION PHARMACAL | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 02057824 | GEN-PINDOLOL TAB 15MG | GENPHARM ULC | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 02057816 | MYLAN-PINDOLOL | MYLAN PHARMACEUTICALS ULC | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 02057808 | MYLAN-PINDOLOL | MYLAN PHARMACEUTICALS ULC | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 00886009 | NU-PINDOL TAB 10MG | NU-PHARM INC | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 00886130 | NU-PINDOL TAB 15MG | NU-PHARM INC | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 00886149 | NU-PINDOL TAB 5MG | NU-PHARM INC | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 00828424 | PINDOLOL-10 TAB 10MG | PRO DOC LIMITEE | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 00828432 | PINDOLOL-15 TAB 15MG | PRO DOC LIMITEE | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 00828416 | PINDOLOL-5 TAB 5MG | PRO DOC LIMITEE | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 02231537 | PMS-PINDOLOL | PHARMASCIENCE INC | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 02231536 | PMS-PINDOLOL | PHARMASCIENCE INC | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 02231539 | PMS-PINDOLOL | PHARMASCIENCE INC | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 02261804 | SANDOZ-PINDOLOL | SANDOZ CANADA INCORPORATED | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 02261782 | SANDOZ-PINDOLOL | SANDOZ CANADA INCORPORATED | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 02261790 | SANDOZ-PINDOLOL | SANDOZ CANADA INCORPORATED | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 00818593 | SYN-PINDOLOL TAB 10MG | SYNCARE PHARMACEUTICAL INC. | Tablet | PINDOLOL 10 MG | Cancelled Post Market |
| 00818607 | SYN-PINDOLOL TAB 15MG | SYNCARE PHARMACEUTICAL INC. | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 00818615 | SYN-PINDOLOL TAB 5MG | SYNCARE PHARMACEUTICAL INC. | Tablet | PINDOLOL 5 MG | Cancelled Post Market |
| 00568627 | VISKAZIDE | XEDITON PHARMACEUTICALS INC | Tablet | PINDOLOL 10 MG; HYDROCHLOROTHIAZIDE 25 MG | Dormant |
| 00417289 | VISKEN | TRIBUTE PHARMACEUTICALS CANADA INC | Tablet | PINDOLOL 15 MG | Cancelled Post Market |
| 00443174 | VISKEN | XEDITON PHARMACEUTICALS INC | Tablet | PINDOLOL 10 MG | Dormant |
| 00417270 | VISKEN | XEDITON PHARMACEUTICALS INC | Tablet | PINDOLOL 5 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 25942 | 2021-05-27 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERSHIP |
| 20915 | 2018-05-30 | New Drug Submission (NDS) | MERGER - BUYOUT |
| 17200 | 2015-08-14 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBERS |
| 4026 | 1997-08-12 | New Drug Submission (NDS) |
International API supply for PINDOLOL
1 valid EDQM Certificates of Suitability from 1 holders. 2 active FDA Drug Master Files.
Request a quote for VISKAZIDE